Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04108481 · ClinicalTrials.gov registry record · Phase 1
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
A Phase 1 study, sponsored by University of Iowa.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT04108481 is a Phase 1 study that was terminated before completion, run by University of Iowa. The registered enrollment target is 5 participants.
The verdict
NCT04108481, a Phase 1 study, was terminated before completion, sponsored by University of Iowa.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This clinical trial will be conducted as a single-center, open-label, Phase I/2 trial to evaluate the feasibility and safety of Yttrium-90 radioembolization (Y90-RE) in combination with a fixed dose of of immunotherapy (durvalumab - 750 mg) in subjects with liver-predominant, metastatic colorectal cancer (mCRC), which is mismatch repair proficient/microsatellite stable (pMMR/MSS).
Interventions
- DRUG Durvalumab
- RADIATION Yttrium-90 RadioEmbolization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-10-05 |
| Est. Completion | 2023-11-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04108481
The ClinicalTrials.gov registry entry for NCT04108481 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Durvalumab is the first listed.
NCT04108481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04108481 about?
NCT04108481 is a clinical study titled "Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer". This clinical trial will be conducted as a single-center, open-label, Phase I/2 trial to evaluate the feasibility and safety of Yttrium-90 radioembolization (Y90-RE) in combination with a fixed dose of of immunotherapy (durvalumab - 750 mg) in subjects with liver-predominant, metastatic colorectal c...
What is the current status of trial NCT04108481?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2020-10-05. Estimated completion is 2023-11-17.
What interventions are being tested in trial NCT04108481?
The interventions under investigation include: Durvalumab (DRUG), Yttrium-90 RadioEmbolization (RADIATION).
Who is sponsoring clinical trial NCT04108481?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.